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Abstract
Background: Despite the large number of drug-resistant tuberculosis (TB) cases in China, few studies have comprehensively
analyzed the drug resistance-associated gene mutations and genotypes in relation to the clinical characteristics of M.
tuberculosis (Mtb) isolates.
Methodology/Principal Findings: We thus analyzed the phenotypic and genotypic drug resistance profiles of 115 Mtb
clinical isolates recovered from a tuberculosis referral hospital in Beijing, China. We also performed genotyping by 28 loci
MIRU-VNTR analysis. Socio-demographic and clinical data were retrieved from medical records and analyzed. In total, 78
types of mutations (including 42 previously reported and 36 newly identified ones) were identified in 115 Mtb clinical
isolates. There was significant correlation between phenotypic and genotypic drug resistance rates for first-line anti-TB
drugs (P,0.001). Genotyping revealed 101 MIRU-VNTR types, with 20 isolates (17.4%) being clustered and 95 isolates
(82.6%) having unique genotypes. Higher proportion of re-treatment cases was observed among patients with clustered
isolates than those with unique MIRU-VNTR genotypes (75.0% vs. 41.1%). Moreover, clinical epidemiological links were
identified among patients infected by Mtb strains belonging to the same clusters, suggesting a potential of transmission
among patients.
Conclusions/Significance: Our study provided information on novel potential drug resistance-associated mutations in Mtb.
In addition, the genotyping data from our study suggested that enforcement of the implementation of genotyping in
diagnostic routines would provide important information for better monitor and control of TB transmission.
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Introduction
Tuberculosis (TB) remains a major infectious and deadly disease
in the world. In addition, multidrug resistance (MDR) and
extensively drug-resistance (XDR) pose a more serious problem
for TB control. WHO reported that about 8.6 million people
developed TB, and 1.3 million died from the disease in 2012. India
and China alone accounted for 26% and 12% of global cases,
respectively. In addition, the global estimate of the burden of
MDR-TB was 300, 000 cases among notified TB patients in 2012.
India and China were the two countries estimated to have the
largest numbers of TB patients with MDR-TB [1]. Therefore,
there is an urgent need to better understand the molecular
epidemiology and clinical characteristics of drug-resistant M.
tuberculosis (Mtb) isolates, so as to provide knowledge for rapid
molecular diagnosis for and better management of drug-resistant
TB.
Despite the high TB burden and large number of drug-resistant
TB cases in China, relatively few studies have performed
comprehensive analysis of drug resistance-associated mutations
of clinical Mtb isolates, their genotypes, as well as their association
with clinical characteristics. We previously observed high rates of
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MDR- and XDR-TB among patients from a TB referral hospital
in Beijing, China [2]. In addition, we established a TBDReaMDB
database-coupled automatic analysis for drug resistance-associated
mutations in Mtb isolates [3]. In this study, we further applied this
method to perform comprehensive analysis of the drug resistance-
associated mutations (genotypic drug resistance profiles) for a
larger sample of Mtb clinical isolates from hospitalized TB
patients. Molecular genotyping is a useful tool for analyzing Mtb
strain diversity and transmission patterns, especially in high
incidence settings such as TB referral hospitals. Genotyping
methods based on variable number of tandem repeats (VNTR) of
mycobacterial interspersed repetitive units (MIRU) have become
popular methods used for TB epidemiological analysis [4,5]. We
thus also evaluated the genotypic population structure for the Mtb
isolates based on 28 loci MIRU-VNTR genotyping analysis and its
correlation with drug resistance associated mutations and clinical
characteristics and epidemiology. Our study added to the growing
list of potential TB drug resistance-associated mutations, which
could be invaluable in applying MDR- and XDR-TB molecular
detection tests. In addition, the genotyping data from our study
suggested that enforcement of the implementation of genotyping
in diagnostic routines would provide important information for
better monitor and control of TB transmission.
Materials and Methods
Ethics statement
The investigation protocols used in this study were approved by
the institutional ethics committee of the 309 Hospital, Beijing,
China. Written informed consent for Mtb isolates to be collected
as well as for their information to be stored in the hospital database
for research purposes was provided by participants. Written
informed consent was obtained from the next of kin, caretakers, or
guardians on the behalf of the minors/children participants
involved in this study. Permission for using the information in the
medical records of the patients for research purposes was obtained
from the 309 Hospital. The Institute ethics committee of the 309
Hospital and the Institute of Microbiology, Chinese Academy of
Sciences approved this study.
Mtb isolates, drug susceptibility testing and detection of
drug resistance-associated mutations
Mtb isolates used in this study were obtained from TB patients
being treated in the 309 Hospital, a TB referral hospital located in
Beijing, China over a 3-year period (January 1, 2009–December
31, 2011). A total of 3860 culture positive TB patients were
diagnosed and treated in the 309 Hospital during 2009–2011. Of
these, 150 non-repetitive Mtb isolates were randomly selected to
obtain pure cultures for further confirmation by p-nitrobenzoic
acid and thiophene carboxylic acid hydrazine resistance tests as
well as 16S rDNA sequencing analysis. Thirty-five isolates were
excluded as a result of contaminated cultures or ambiguous
sequencing results. The remaining 115 isolates were then subjected
to DST, sequencing for drug resistance-associated gene mutations,
and genotyping analysis. Epidemiologic and clinical data of the
patients were extracted from the subjects’ medical records. Mtb
isolates were cultured using the BACTEC 960 system (Becton
Dickinson Diagnostic Systems, Sparks, MD, USA) according to
the manufacturer’s instructions. The drug susceptibility testing
(DST) were conducted according to the WHO guidelines as
described previously [2]. Identification of drug resistance-associ-
ated mutations of Mtb isolates was conducted as described
previously [3]. Written informed consent was obtained from
participants.
MIRU-VNTR genotyping of Mtb isolates
Deletion-targeted multiplex PCR (DTM-PCR) method was
used initially to identify the Beijing strains [6]. The Mtb isolates
were further genotyped by a 28 loci MIRU-VNTR method based
on the 24 loci described by Supply et al. [4,7] as well as the four
hyper variable loci (1982, 3232, 3820, and 4120) described by Gao
et al. [8] and Supply et al. [9]. The amplicons were evaluated on
the 2% standard agarose gels by using a 100-bp DNA ladder
(Takara), and sizing of the various VNTR alleles was done with
the Peak Scanner Software v1.0 (PE Applied Biosystems). The
number of repeats at each locus of MIRUs was determined and
numerical values were assigned accordingly. Genetic clusters were
defined as a group of two or more isolates exhibiting the same
MIRU-VNTR pattern. The reference strain H37Rv was run as an
additional control.
Phylogenetic analysis
The phylogenetic tree based on the 28 loci MIRU-VNTR data
was constructed using PAUP 4.0b software [10] with UPGMA
(unweighted pair-group method with arithmetic means) method.
Statistical analyses
All data were analyzed using the SPSS software (15.0 version).
Comparisons of categorical variables were performed using the
Pearson Chi-square test to compare different groups. A P value of
,0.05 was considered to be statistically significant.
Results
General characteristics of the study subjects
A total of 115 non-repetitive Mtb isolates collected during
2009–2011 period were included in this study. The TB patients
from whom the Mtb isolates were obtained included 53 susceptible
TB cases, 21 MDR-TB cases, 17 XDR-TB cases, and 24 other
types of TB cases (drug-resistant TB cases excluding MDR- and
XDR-TB). All cases were HIV negative. The median age was 37
(range 14–86). Sixty-nine (60.0%) patients were male and 46
(40.0%) were female. Sixty-one (53.0%) patients were new cases
and 54 (47.0%) were re-treatment cases. More detiled information
on socio-demographic and clinical characteristics of the patients is
shown in Table S1.
Drug resistance-associated gene mutations in Mtb
isolates
We identified 78 types of mutations in drug resistance-
associated genes, including 42 previously reported ones (Table 1)
and 36 newly identified ones (Table 2 and Table 3). More detailed
information on the PCR primers used for as well as the mutations
identified in drug resistance-associated loci in all Mtb isolates were
listed in Table S2 and Table S3, respectively. There was
significant correlation between phenotypic and genotypic drug
resistance rates for first-line anti-TB drugs (P,0.001 for isoniazid,
rifampicin, streptomycin, ethambutol and pyrazinamide by chi-
square test). The percentages of genotypic resistant isolates among
phenotypic resistant isolates for first-line anti-TB drugs varied
between 40.0% to 95.7%. There was also significant correlation
between some of the second-line anti-TB drugs (P,0.001 for
ofloxacin/levofloxacin and kanamycin by chi-square test). The
percentages of genotypic resistant isolates among phenotypic
resistant isolates for second-line anti-TB drugs varied between 0%
to 41.5% (Table S4).
Molecular Characteristics of Mycobacterium tuberculosis
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MIRU-VNTR genotype profiles of the Mtb isolates
Initially, we applied the DTM PCR method to identify the
Beijing genotype strains, and the majority of the studied isolates
belonged to Beijing genotype (96.5%, 111/115), which limits the
usefulness of spoligotyping. We thus further performed 28 loci
MIRU-VNTR analyses to genotype all the isolates. The detailed
information on the PCR primers used as well as the 28 loci
MIRU-VNTR genotype profiles for each isolates are listed in
Table S2 and Table S5, respectively. A total of 101 MIRU-VNTR
genotypes were detected. Twenty isolates (17.4%) were clustered
and 95 isolates (82.6%) had unique genotypes (Fig. 1 and Table
S6).
Association between clinical characteristics of the
patients and MIRU-VNTR genotype clustering
Comparison of demographic and clinical characteristics of the
patients with clustered vs. unique genotype patterns are shown in
Table 4. We observed higher proportion of re-treatment cases
among patients with clustered isolates than those with unique
MIRU-VNTR genotypes (75.0% vs. 41.1%). However, there was
no obvious association between the drug resistance as well as
several other characteristics of patients (such as gender, age,
underlying diseases, and geographic location, etc.) with the
clustered MIRU-VNTR genotypes of the corresponding Mtb
isolates. By further examining the clinical data of the clustered
isolates, we noticed that two groups of clustered isolates had
clinical epidemiological links. Specifically, Mtb 1056 (susceptible)
Figure 1. UPGMA tree based on the 28 loci MIRU-VNTR data of 115 M. tuberculosis isolates. Note: M=MDR; X= XDR.
doi:10.1371/journal.pone.0110209.g001
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Table 4. Demographic and clinical characteristics of the patients for clustered vs. unique patterns.
Characteristics
Clustered
n=20 (%)
Unique patterns
n=95 (%) P value
Gender 0.132
Male 9 (45.0) 60 (63.2)
Female 11 (55.0) 35 (36.8)
Age group, years 0.722
,14 0 1 (1.1)
15–29 6 (30.0) 38 (40.0)
30–44 5 (25.0) 20 (21.1)
45–59 4 (20.0) 15 (15.8)
60–74 3 (15.0) 18 (18.9)
.75 2 (10.0) 3 (3.2)
Marital status 0.554
Married 16 (80.0) 70 (73.7)
Single 4 (20.0) 25 (26.3)
Residence situation 0.623
Beijing resident 5 (25.0) 29 (30.5)
Migrant 15 (75.0) 66 (69.5)
Ethnicity 0.210
The largest group (Han) 20 (100.0) 88 (92.6)
Ethnic groups 0 7 (7.4)
Geographic location 0.295
East China 2 (10.0) 7 (7.4)
South China 0 0
North China 11 (55.0) 72 (75.8)
Central China 2 (10.0) 4 (4.2)
Northeast China 4 (20.0) 7 (7.4)
Southwest China 1 (5.0) 2 (2.1)
Northwest China 0 3 (3.2)
TB treatment history 0.006
New cases 5 (25.0) 56 (58.9)
Re-treatment cases 15 (75.0) 39 (41.1)
Underlying diseases
Diabetes mellitus 4 (20.0) 14 (14.7) 0.556
Hypertension 2 (10.0) 9 (9.5) 0.942
Abnormal liver function 5 (25.0) 12 (12.6) 0.157
Chronic obstructive pulmonary disease 1 (5.0) 4 (4.2) 0.875
Sites of TB 0.107
Extrapulmonary TB 0 14 (14.7)
Pulmonary TB 12 (60.0) 58 (61.1)
Pulmonary and
extrapulmonary TB
8 (40.0) 23 (24.2)
Radiological findings at onset 0.066
Non-cavitary 6 (30.0) 50 (52.6)
Cavitary disease 14 (70.0) 45 (47.4)
Drug resistance types 0.110
Susceptible 13 (65.0) 40 (42.1)
MDR 1 (5.0) 20 (21.1)
XDR 4 (20.0) 13 (13.7)
Other types 2 (10.0) 22 (23.2)
Treatment outcome 0.083
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and 1059 (XDR) were isolated from patients having overlapping
hospitalization dates in Tuberculosis ward 2, while Mtb 1053
(XDR) and 1057 (XDR) were obtained from patients having
overlapping hospitalization dates in Tuberculosis ward 3. The
more detailed epidemiological and clinical information of the
patients from whom those clustered isolates were isolated were
shown in Supplementary Table S7.
Phylogenetic analysis of Mtb isolates
A total of 38,355 bp covering drug resistance-associated loci in
Mtb were used for analysis as described in a previous study [3].
From the UPGMA tree based on the 28 loci MIRU-VNTR data
of Mtb isolates, we observed that clustered isolates contained both
susceptible and drug-resistant isolates (Fig. 1).
Discussion
Early detection of drug resistance in Mtb is important for the
successful treatment of TB. New tools for rapid and cost-effective
diagnosis of drug resistance in Mtb isolates are urgently needed to
control drug-resistant TB, especially the more dangerous MDR-
and XDR- TB epidemics. Molecular diagnostics could potentially
fill this need but require comprehensive information on the type
and frequency of specific drug resistance-associated mutations. A
recent study by Zhang et al. reported that through sequencing 161
Mtb isolates with a range of drug resistance profiles, they
discovered 72 new genes, 28 intergenic regions, 11 non-
synonymous SNPs and 10 intergenic region SNPs with strong
and consistent associations with drug resistance in Mtb [11]. In
this study, we further identified 36 unreported mutations in drug
resistance-associated genes in clinical Mtb isolates. Our study adds
to the growing body of knowledge on potential drug resistance-
associated mutations in Mtb, which could lead to the development
of rapid and more comprehensive molecular diagnostic methods
for drug-resistant TB.
Some mutations we identified were seen in both susceptible and
resistant isolates. For example, Rv1592c T70 (del) (INH), gidB
S100F (SM), embC R927 (EMB), ethAQ360 H (ETH), gidB E92D
(SM), gyrA (S95T) and gyrA E21Q (OFX, LVX) etc. were seen in
identical or similar prevalence between susceptible and resistant
isolates, thus those mutations should not be associated with drug
resistance. Instead, they could be considered as reference specific
mutations or phylogenetic informative mutations. The relatively
low correlation between the phenotypic and genotypic drug
resistance profiles for some drugs were consistent with our
previous study and also some other studies [3,12]. Consistent
with several previous studies, our observations showed that certain
mutations were more frequently identified in resistant isolates vs.
susceptible isolates and thus could serve as useful marker for rapid
detection of resistance in the clinical Mtb isolates. For example,
S315T and R463L in katG (for isoniazid resistance); S531L in
rpoB; K43R and K88R in rpsL (for streptomycin resistance);
M306V in embB (for ethambutol resistance); D94G and A90V in
gyrA (for fluoroquinolone resistance); and G1332A and A1401G in
rrs (for kanamycin resistance), etc. [13–15]. Except for those
known drug resistance mutations, our studies also revealed a few
more newly identified potential drug resistance mutations. For
example, A1081 (del) in rpoB, A908C in rrs, A119D, A193 and
A205 in gidB, A28 (del) in pncA, and A1789 (del) in rpoB. We
then performed genetic studies by creating point mutation in the
susceptible reference strain H37Rv using the pJV53K system [16]
for those newly identified potential drug resistance-associated
mutations, but failed to confirm their roles in causing drug
resistance (data not shown). Our study further confirmed the
notion that the genetic basis of drug resistance is more complex
than previously anticipated, and a single point mutation could
possibly contribute to but is not efficient for drug resistance
[17,18].
Analysis of VNTR profiles specific to endemic strains in certain
settings may be useful to identify the sources of outbreaks and
transmission pathways. For example, genotyping analysis of
MDR-TB isolates revealed that active transmission of MDR-
and XDR-TB is taking place in Portugal, and that the high
prevalence of observed XDR-TB is due to the continued
transmission of particular genetic clusters [19,20]. But another
recent study from Mexico showed that almost all MDR cases
studied were epidemiologically unrelated, indicating that the
genetic variations observed among those strains are suggestive of
emergence of acquired drug-resistance during the course of
treatment [21]. A large proportion of the analyzed cases in our
study were primary MDR- or XDR-TB. In addition, the clustered
MDR-, and XDR-TB cases among the new cases strongly
indicated that those patients had been primarily infected with
those highly drug-resistant Mtb strains. The observation that
clustered isolates contained both susceptible and drug-resistant
isolates in the UPGMA tree suggested that the drug resistance
traits of Mtb strains are not conserved within defined strain
clusters but rather that individual isolates within each cluster have
evolved unique characteristics during long-term antibiotic treat-
ment and complicated microbe-host interaction process. This
observation further confirmed the previous notion that drug-
resistant Mtb isolates have evolved and acquired different
mutations independently [3]. We also observed higher proportion
of re-treatment cases among patients with clustered isolates than
those with unique MIRU-VNTR genotypes. This indicates that
those re-treatment cases could be linked with reactivation or
recent transmission of new strains. We did notice that several
groups of isolates among clustered isolates had clinical epidemi-
ological links, but since those epidemiologically linked clustered
isolates had similar but not identical phenotypic and genotypic
drug resistance profiles, thus those data could not support the
Table 4. Cont.
Characteristics
Clustered
n=20 (%)
Unique patterns
n=95 (%) P value
Cure 15 (75.0) 79 (83.2)
Died 1 (5.0) 0
No data 4 (20.0) 16 (16.8)
doi:10.1371/journal.pone.0110209.t004
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incidence of patient-to-patient transmission during their hospital-
ization. A previous study indicated the limitations of using MIRU-
VNTR typing and epidemiological investigations to detect
transmission of Mtb in high burden settings and suggested that
whole-genome sequencing (WGS) could provide better solution for
tracing the transmission of Mtb in such settings [22]. Thus WGS
could be used in the future to better discriminate the possibility of
direct transmission events defined by the MIRU-VNTR typing in
this study. Nevertheless, since the clustered isolates have a
potential of transmission among patients as suggested by several
previous studies [19,20,23], thus early detection of those isolates
and strengthening of control measures to prevent transmission of
them are warranted.
A limitation of this study is a possible sampling bias, which could
be caused by the following factors. First, the sampling of the
participants was not completely randomized but was based on
voluntary participation of the patients and availability of the pure
cultures of the isolates. Second, since the sample size is relatively
small and some mutations were detected at a relatively low
frequency, thus the statistical analysis used to identify potential
drug resistance mutations in this study might not be suitable for
some mutations. For example, D516V in rpoB was previously
considered to be a drug resistance mutation [24], while the P value
for this mutation was higher than 0.05. By contrast, a couple of
mutations that were known not associated with drug resistance,
such as gidB E92D [25] and gyrA S95T [26], were found with a P
value lower than 0.05. Third, the sampling was not continuously
done, which could lead to reduced clustering of cases. Neverthe-
less, this study provided important baseline data that may be used
to understand and monitor the molecular epidemiology of Mtb
isolates in China. Further studies are warranted to better
understand the detailed molecular mechanisms in MDR- and
XDR-Mtb isolates.
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